10/30/2003 3:28:54 PM ET


    SWISS MEDICA SIGNS INFOMERCAL TELEVISION MARKETING AGREEMENT WITH MEDIACORP
    WORLDWIDE FOR O24 PAIN RELIEF
      


    FOR IMMEDIATE RELEASE

    Stock Symbol: OTC BB:SWME
    October 30, 2003

    SWISS MEDICA SIGNS INFOMERCAL TELEVISION MARKETING AGREEMENT WITH MEDIACORP
    WORLDWIDE FOR O24 PAIN RELIEF

    Toronto, Canada – Swiss Medica Inc. announced today that its new O24 Pain Relief Product has been chosen
    by MediaCorp Worldwide to participate in its joint venture infomercial, direct response television marketing
    program.

    MediaCorp will produce and air a short format “infomercial” to begin marketing the product in select regions of
    the U.S. for a two week test period after which the infomercial will be aired nationally on a daily basis. As part of
    the joint venture agreement, MCW will establish and maintain an 800 number staffed by 24-hour operators to
    support sales of the product. They will also handle all credit card processing, collecting and shipping to the end
    user.

    Production of the infomercial is set to take place in November 2003, with the first ads hitting the airwaves by
    early 2004.

    MediaCorp President, Earl Pardo, stated, “We are excited about entering into the agreement with Swiss Medica
    and hope to have a successful test market with the O24 Pain Relief product.” He added that Direct Response
    Television has proven itself to be a highly effective means of “leveling the playing field” for growing companies
    bringing innovative new products into the marketplace.

    “We are pleased to partner with MediaCorp on this joint venture. The infomercial platform will give us the
    opportunity to showcase our O24 penetrating pain relief product in millions of American households,” said Mr.
    Johnson, President and COO of Swiss Medica. Mr. Johnson went on to say, “This can only have a positive effect
    in terms of building both brand recognition and sales revenue.”

    A non-patented pain relief product recently achieved sales in excess of $75 million in its first year of distribution
    via an infomercial. The infomercial industry has grown to a multi billion dollar distribution channel that allows
    multinationals and entrepreneurs to educate consumers on the merits of their products/services in addition to
    allowing for direct sales.

    MediaCorp Worldwide has a well-established history of bringing new products to market. Products such as
    ‘Quick 10’, ‘The Salad Blaster’ and ‘the Rolling Styler™’ have utilized MediaCorp’s expertise to take them from
    unknown, innovative new products to worldwide distribution.

    MediaCorp Worldwide has also turned the brand recognition generated through television campaigns into highly
    coveted spots on shelves of national retail chains. MediaCorp’s network of sales representatives, located
    throughout the United States and Canada, have direct access to buyers from major specialty stores and mass
    merchandisers from coast to coast.

    Founded in 1995, MediaCorp Worldwide has become one of the leading development and distribution
    companies in the U.S. focusing on innovative products with short-form commercials.
    Website: http://www.mediacorpworldwide.com/


    About Swiss Medica Inc.

    Swiss Medica Inc. is focused on acquiring over-the-counter bioscience products with demonstrated competitive
    advantages and increasing their revenues by focused sales and marketing efforts in selected distribution
    channels including retail, direct sales, direct response, and e-commerce. Swiss Medica’s mission is to be a world
    leader in the acquisition and commercialization of life enhancing bioscience products that improve quality of
    lives. Please visit our websites at www.swissmedica.com and www.O24zone.com.

    Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
    United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica’s services, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    Investor Relations Contact:

    Dave Jones: 705 495 0022
    djones@swissmedica.com